Nguyen et al. revisit one of the longest-running controversies in men’s health: does PSA screening actually save lives? Looking across more than 720,000 men from five randomized controlled trials with follow-up extending as long as 23 years, the answer from this updated meta-analysis is yes. PSA-based screening was associated with a significant reduction in PCa–specific mortality, and the benefit became more apparent the longer patients were followed. This is important because many earlier analyses concluded that PSA screening had little or no impact on survival, largely based on shorter follow-up periods.

The authors point to confounding factors where men in the non-screening groups still underwent PSA testing, along with inconsistent screening intensity across studies. In other words, the comparison between screened and unscreened groups became blurred over time. The real message is that PCa often progresses slowly, and understanding the value of screening may require decades of observation.

PSA remains useful, but its biggest weakness is specificity. Elevated levels can come from cancer, but also from benign enlargement, prostatitis, or infection. This can lead many men toward biopsies they may not actually need. In this study of 307 men undergoing prostate biopsy, several inflammation-based blood markers were significantly higher in patients ultimately diagnosed with PCa.

What makes this interesting is that some of these inflammatory indices performed surprisingly well when combined with PSA. In fact, combining inflammatory markers with PSA improved overall predictive accuracy even further. The practical appeal is obvious: these markers are derived from routine blood counts already obtained in many patients, meaning no expensive new testing is required. These markers were far better at helping identify the presence of cancer than determining how aggressive the cancer might be.

Li et al. describe something that feels much closer to the future of PCa screening: a handheld device capable of detecting sarcosine in urine samples within minutes. Sarcosine is a metabolite that has been associated with PCa progression and aggressiveness, with levels rising as disease advances from localized to metastatic cancer. Unlike PSA, urine-based sarcosine testing offers a completely non-invasive approach with the potential for rapid screening and monitoring.

The entire fluorescence detection device costs only about $27 to build, fits in the palm of a hand, and was able to successfully distinguish PCa patients from healthy controls using real urine samples. The system measures sarcosine concentrations with surprisingly high sensitivity. Obviously, this is still early-stage technology and far from replacing established diagnostics. Still, I’m excited by the prospect of PCa detection moving toward less invasive and potentially more accessible forms of screening.

Nanomedicine. The basic idea is surprisingly simple: build microscopic delivery systems capable of carrying drugs directly to PCa cells while minimizing exposure to the rest of the body. PCa tumors can vary dramatically in behavior, aggressiveness and treatment response, particularly in advanced or treatment-resistant forms. Nanoparticles may eventually help overcome some of that complexity by improving drug targeting and reducing toxicity.

These nanoparticle systems are being designed not only to deliver chemotherapy, but also gene therapy, immunotherapy and radiotherapy. Some platforms are engineered to recognize specific PCa markers like PSMA, allowing drugs to accumulate more selectively inside tumor tissue while sparing normal cells.

The authors also discuss future directions involving AI-guided nanoparticle engineering and “digital twin” treatment modeling, where therapies could theoretically be customized to an individual patient’s tumor biology. Obviously, much of this remains developmental, but it’s becoming apparent that PCa therapy is gradually shifting from generalized treatment toward increasingly precise biologic targeting.

Kulshekar et al. explored which lifestyle factors truly influence PCa risk? In this hospital-based study, the strongest associations were surprisingly linked to coffee intake and meat consumption (!), both of which were associated with a lower likelihood of PCa diagnosis after statistical adjustment. Coffee, in particular, remained strongly protective, with the authors pointing toward compounds such as cafestol, kahweol, caffeine and polyphenols that may influence inflammation, oxidative stress, DNA repair and tumor pathways.

Smoking, tobacco chewing, alcohol use, tea intake, farming exposures and meat consumption all produced conflicting findings when compared with prior studies. That’s probably one of the most interesting points here. PCa risk is unlikely to depend on a single food or habit. Instead, it appears to emerge from the cumulative interaction between diet, environmental exposures, inflammation, metabolism and genetics over decades.

Patel and Keogh looked at something that sounds obvious but is often poorly implemented in real clinical practice: getting PCa patients to actually move. The paper explored how healthcare practitioners encourage physical activity throughout the PCa journey, particularly for men receiving androgen deprivation therapy (ADT). Clinicians consistently viewed exercise not as an optional “wellness extra,” but as a legitimate therapeutic strategy. Practitioners repeatedly linked physical activity to preserving muscle mass, maintaining bone density, reducing fatigue, improving cardiovascular health, supporting mood and helping patients maintain independence in daily life.

Several clinicians encouraged simple, achievable movement like walking to the mailbox, standing from a chair repeatedly, light resistance exercises with household items, or gradually increasing daily activity. The paper also reinforced something I discuss frequently: exercise during cancer treatment does not need to look like elite athletic training to produce meaningful biologic benefits. Physical activity is no longer being viewed merely as supportive care in PCa. Increasingly, it is being treated as part of the treatment strategy itself.